Pennsylvania Hemp THC Regulation: Laws, Testing & Age Limits Explained

Executive Summary

Pennsylvania State Senator Dawn Keefer introduced the Pennsylvania Hemp and Cannabinoid Act in September 2026, seeking to establish the first comprehensive regulatory framework for hemp-derived THC products in the Commonwealth. The Republican-sponsored legislation would preserve the legal status of delta-8 THC, delta-10 THC, and other hemp cannabinoids while implementing age restrictions, mandatory third-party testing, product registration requirements, and standardized labeling protocols. The bill arrives amid growing concern from state regulators and law enforcement about unregulated intoxicating hemp products sold in gas stations, convenience stores, and smoke shops across Pennsylvania. With the state's medical marijuana program serving over 400,000 registered patients but no adult-use cannabis framework, hemp-derived THC products have filled a legal gray area since the 2018 Farm Bill federally legalized hemp containing less than 0.3% delta-9 THC. Keefer's proposal represents a middle path between outright prohibition—pursued by at least 15 states—and the current unregulated marketplace, where products vary wildly in potency, purity, and safety. The legislation's fate will test whether Pennsylvania can balance consumer access, public health protections, and the interests of both the established medical cannabis industry and the emerging hemp sector.

Why Pennsylvania's Hemp THC Regulation Matters

Pennsylvania's approach to hemp-derived intoxicating cannabinoids will affect millions of consumers, hundreds of businesses, and set precedent for other states navigating the same regulatory challenge. The Commonwealth's population of 13 million makes it the fifth-largest state, and its regulatory decisions carry weight in the Mid-Atlantic region and beyond. The economic stakes are substantial. Pennsylvania's hemp industry generated an estimated $120 million in retail sales during 2025, according to industry estimates, with hemp-derived THC products representing approximately 60% of that total. More than 800 retail locations across the state currently sell these products, from dedicated CBD shops to gas station chains. An unregulated market crash—through either prohibition or federal enforcement—would eliminate hundreds of jobs and millions in tax revenue. For consumers, the regulatory question is existential. Pennsylvania residents currently purchase delta-8 THC, THCA flower, and other hemp cannabinoids without age verification, potency limits, or testing requirements in many locations. Public health officials have documented emergency room visits related to hemp THC products, though comprehensive data remains limited. The Pennsylvania Department of Health reported 47 adverse event reports associated with hemp-derived cannabinoids in 2025, up from 12 in 2023. The medical marijuana industry watches closely. Pennsylvania's medical cannabis program, operational since 2018, generated $1.8 billion in sales during 2025 through 36 licensed grower-processors and 192 dispensaries. Medical operators argue that untested, unregulated hemp products undermine their heavily regulated and taxed business model. Some medical dispensaries have begun selling hemp products alongside medical cannabis, creating competitive tensions. Patient advocates emphasize access concerns. Medical marijuana cards in Pennsylvania cost $50 annually, require physician certification, and limit qualifying conditions. Many patients report using hemp-derived products as more affordable, accessible alternatives—despite unknown quality and potency. Regulation without prohibition could protect these consumers while establishing safety standards.

Background and History: From Farm Bill to State Crossroads

The 2018 Farm Bill Creates a Legal Gray Area

The federal Agriculture Improvement Act of 2018, signed by President Donald Trump on December 20, 2018, removed hemp from the Controlled Substances Act and legalized hemp-derived products containing no more than 0.3% delta-9 THC on a dry weight basis. This single threshold—0.3% delta-9 THC—created an unintended loophole that entrepreneurs quickly exploited. The Farm Bill's authors focused on traditional hemp products: fiber, seed, and CBD extracted from hemp. The legislation defined hemp under 7 U.S.C. § 1639o as "the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis." This definition said nothing about other THC isomers. Chemists recognized that delta-8 THC, delta-10 THC, THC-O, and other intoxicating cannabinoids could be synthesized or converted from CBD extracted from legal hemp. By 2020, delta-8 THC products appeared in smoke shops and online retailers. By 2021, the market exploded.

Pennsylvania's Initial Hemp Program

Pennsylvania established its hemp research and cultivation program in 2016 under the Plant Sanitation Act, two years before federal legalization. The Pennsylvania Department of Agriculture assumed regulatory authority, issuing permits for hemp cultivation and processing focused on industrial applications and CBD extraction. Following the 2018 Farm Bill, Pennsylvania expanded its program in 2019 to align with federal law. The Department of Agriculture submitted a state hemp plan to the U.S. Department of Agriculture, receiving approval in August 2019. This plan addressed cultivation, testing for THC compliance, and disposal of non-compliant crops. It did not contemplate intoxicating hemp-derived products. By 2021, Pennsylvania had licensed 247 hemp growers cultivating 3,400 acres. The industry focused primarily on CBD extraction for tinctures, topicals, and other non-intoxicating products. Hemp flower sales remained legal but represented a small market segment.

The Delta-8 Boom and Regulatory Silence

Delta-8 THC products flooded Pennsylvania retail locations beginning in late 2020, with state regulators offering no clear guidance on their legal status for nearly two years. Retailers interpreted federal hemp legalization and state silence as implicit permission. The Pennsylvania Department of Agriculture, which regulates hemp cultivation, maintained it had no authority over finished hemp products sold at retail. The Department of Health, which oversees the medical marijuana program, similarly claimed no jurisdiction over federally legal hemp. The Pennsylvania Liquor Control Board, which regulates alcohol and tobacco, did not consider hemp products within its purview. This regulatory vacuum allowed rapid market growth. By mid-2022, delta-8 THC vape cartridges, gummies, and flower appeared in convenience stores, gas stations, and smoke shops statewide. Prices undercut the medical marijuana market significantly—a delta-8 vape cartridge retailed for $25-35 compared to $50-70 for equivalent medical cannabis products.

Law Enforcement and Public Health Concerns Emerge

Pennsylvania law enforcement agencies began expressing concern about hemp THC products in 2022, citing difficulties distinguishing legal hemp from illegal marijuana and reports of youth access. The Pennsylvania District Attorneys Association issued a statement in June 2022 calling for state legislation to address "intoxicating hemp products that circumvent the medical marijuana program." The Pennsylvania chapter of the American Academy of Pediatrics raised alarm about marketing practices in October 2022, documenting hemp THC products sold in packaging resembling candy brands and positioned near checkout counters accessible to minors. A survey of 50 retail locations in Philadelphia, Pittsburgh, and Harrisburg found that 38 sold hemp THC products to underage decoy shoppers without requesting identification. Emergency departments reported increased presentations involving hemp-derived cannabinoids, though data collection remained inconsistent. The Pennsylvania Poison Control Center logged 47 calls related to delta-8 THC in 2022, compared to 8 in 2021. Most cases involved unintentional pediatric ingestion of gummies.

Federal Regulatory Developments

The Drug Enforcement Administration issued an Interim Final Rule in August 2020 stating that "all synthetically derived tetrahydrocannabinols remain schedule I controlled substances," creating legal uncertainty about chemically converted delta-8 THC. The DEA's position, published at 85 Fed. Reg. 51639, suggested that delta-8 THC produced through chemical conversion of CBD might be illegal, even if derived from legal hemp. Industry groups challenged this interpretation, arguing that the Farm Bill legalized "all derivatives, extracts, cannabinoids, isomers" from hemp, regardless of processing method. Federal courts have not definitively resolved this question, leaving states to make their own determinations. The Food and Drug Administration maintained that hemp-derived CBD and other cannabinoids in food products or dietary supplements require FDA approval, which no products have received. However, FDA enforcement remained minimal, with the agency issuing warning letters to a handful of companies making egregious health claims but taking no action against the broader market.

State-Level Responses Across the Nation

At least 15 states banned delta-8 THC and similar hemp-derived intoxicants between 2021 and 2026, while others implemented regulatory frameworks. Alaska, Arizona, Arkansas, Colorado, Delaware, Idaho, Iowa, Mississippi, Montana, New York, North Dakota, Rhode Island, Utah, Vermont, and Washington prohibited delta-8 THC through various mechanisms—some via health department rules, others through legislation. States taking regulatory approaches included Kentucky, Louisiana, Minnesota, and Virginia, each establishing testing requirements, age restrictions, and potency limits while preserving legal access. These frameworks typically set THC serving size limits (5-10mg per serving), require certificates of analysis from accredited laboratories, mandate child-resistant packaging, and restrict sales to adults 21 and older. Pennsylvania watched these experiments while its own market continued growing without guardrails.

Pennsylvania Legislative Attempts and Failures

Multiple Pennsylvania legislators introduced bills to address hemp THC products between 2022 and 2026, but none advanced to passage. In March 2023, State Representative Amen Brown (D-Philadelphia) introduced HB 1380, which would have banned all intoxicating hemp-derived cannabinoids. The bill died in committee without a hearing. In June 2024, State Senator Camera Bartolotta (R-Washington) proposed SB 1098, establishing a regulatory framework similar to Senator Keefer's current proposal. That bill included testing requirements and age limits but faced opposition from both prohibition advocates who wanted a complete ban and hemp industry representatives who objected to specific testing protocols. It never reached a floor vote. The Pennsylvania Medical Cannabis Society, representing licensed medical marijuana operators, lobbied for strict regulations or prohibition of hemp THC products, arguing they created unfair competition. The Pennsylvania Hemp Industry Council, representing hemp businesses, advocated for light-touch regulation that would preserve market access. This legislative stalemate left Pennsylvania's hemp THC market in limbo—technically legal under federal law and state silence, but increasingly controversial and vulnerable to sudden prohibition.

Senator Keefer's Pennsylvania Hemp and Cannabinoid Act

Senator Dawn Keefer announced the Pennsylvania Hemp and Cannabinoid Act through a cosponsorship memorandum circulated to colleagues on September 28, 2026, seeking support before formal bill introduction. The Republican senator from York County chairs the Agriculture and Rural Affairs Committee, positioning her strategically to advance hemp legislation. The cosponsorship memo outlines several key regulatory components, though the full legislative text had not been released as of the announcement date.

Age Restrictions and Access Controls

According to Keefer's memo, the legislation would prohibit sales of hemp-derived THC products to anyone under 21 years old. Retailers would face penalties for failing to verify age through government-issued identification. The bill would also ban vending machine sales and require products to be stored behind counters or in locked cases in retail locations that also serve minors.

Product Registration Requirements

The proposal would require manufacturers and distributors of hemp THC products to register with the Pennsylvania Department of Agriculture. Registration would involve submitting product formulations, providing certificates of analysis, and paying annual fees. The fee structure had not been specified in the initial announcement, but similar programs in other states charge $250-1,000 per product SKU annually.

Testing and Laboratory Standards

The Pennsylvania Hemp and Cannabinoid Act would mandate third-party testing of all hemp THC products for potency, pesticides, heavy metals, residual solvents, and microbial contaminants. Testing would need to occur at laboratories accredited to ISO/IEC 17025 standards, the same requirement applied to Pennsylvania's medical marijuana program. Products would require certificates of analysis confirming compliance with safety standards and accurate labeling. The specific contaminant limits and testing protocols would be established through regulations developed by the Department of Agriculture.

Labeling and Packaging Requirements

The legislation would establish standardized labeling requirements including total THC content per package and per serving, ingredient lists, manufacturing and expiration dates, batch numbers for traceability, and health warnings. Packaging would need to be child-resistant, opaque, and resealable where applicable. The bill would prohibit packaging or marketing that appeals to minors, including cartoon characters, bright colors mimicking candy brands, and terms like "candy" or "treats." Products could not make therapeutic or health claims without FDA approval.

Potency Limits and Serving Sizes

While the cosponsorship memo did not specify exact limits, Keefer indicated the legislation would establish "reasonable potency limits per serving" for edible products. Regulatory frameworks in other states typically limit edibles to 5-10mg THC per serving and 50-100mg per package. The Pennsylvania proposal would likely fall within this range.

Enforcement and Penalties

The Department of Agriculture would gain authority to inspect retail locations, test products, and issue violations. Penalties would include fines for non-compliant products, suspension or revocation of registration for repeat violations, and potential criminal charges for sales to minors. The bill would not criminalize possession or consumption by adults.

Key Players and Stakeholder Positions

Senator Dawn Keefer

Dawn Keefer, a Republican representing Pennsylvania's 31st Senatorial District covering York County, has positioned herself as a pragmatic voice on cannabis policy. First elected in 2018, Keefer serves as chair of the Agriculture and Rural Affairs Committee and sits on the Law and Justice Committee, giving her jurisdiction over both agricultural and criminal justice aspects of hemp regulation. Keefer has not supported adult-use marijuana legalization but has backed medical cannabis expansion. Her hemp THC proposal reflects a middle position—preserving legal access while implementing consumer protections. In her announcement, Keefer stated the bill aims to "protect Pennsylvania consumers, particularly children, while supporting responsible businesses and preserving access for adults."

Pennsylvania Department of Agriculture

The Department of Agriculture, led by Secretary Russell Redding, currently regulates hemp cultivation under the state's USDA-approved hemp plan. The agency has advocated for clear legislative authority over hemp-derived products, which currently fall into a regulatory gap. Department officials have expressed support for comprehensive regulation rather than prohibition, recognizing the economic importance of Pennsylvania's hemp industry. The Department would assume significant new responsibilities under Keefer's bill, including product registration, laboratory accreditation, and retail enforcement—functions requiring additional staff and resources.

Pennsylvania Department of Health

The Department of Health oversees the medical marijuana program but has maintained it lacks authority over federally legal hemp products. Health officials have documented adverse events related to hemp THC products and supported regulatory action. The Department has not taken a public position on Keefer's specific proposal but has generally favored testing requirements and age restrictions.

Pennsylvania Medical Cannabis Society

The Pennsylvania Medical Cannabis Society, representing the state's 36 licensed medical marijuana grower-processors, has lobbied for strict regulation or prohibition of hemp THC products. The organization argues that unregulated hemp products undermine the medical program's safety standards and create unfair competition. Medical operators invested hundreds of millions in licensed facilities subject to extensive testing, security, and quality control requirements. They pay effective tax rates near 70% due to Internal Revenue Code Section 280E, which prohibits business deductions for marijuana operations. Hemp businesses face no such restrictions. Some medical cannabis companies have launched hemp product lines to compete, creating internal industry divisions. The Society has not formally endorsed or opposed Keefer's bill, awaiting full legislative text.

Pennsylvania Hemp Industry Council

The Pennsylvania Hemp Industry Council represents hemp farmers, processors, and retailers. The organization has advocated for regulation rather than prohibition, recognizing that some framework is inevitable and preferable to a ban. The Council supports age restrictions and basic testing but has raised concerns about registration costs and compliance timelines that could disadvantage small businesses. Hemp industry representatives worry that overly burdensome regulations could effectively prohibit products by making compliance economically unfeasible, particularly for smaller retailers and manufacturers.

Law Enforcement Organizations

The Pennsylvania District Attorneys Association and Pennsylvania Chiefs of Police Association have called for legislative action on hemp THC products. Law enforcement groups cite difficulties distinguishing legal hemp from illegal marijuana in the field, concerns about impaired driving, and reports of youth access. These organizations have generally favored prohibition over regulation but have indicated they could support a strong regulatory framework with clear enforcement mechanisms.

Public Health and Medical Organizations

The Pennsylvania chapter of the American Academy of Pediatrics has advocated for strict regulation including age limits, potency caps, child-resistant packaging, and marketing restrictions. The Pennsylvania Medical Society has supported testing requirements and physician involvement in cannabinoid product recommendations. These organizations oppose prohibition, recognizing that bans drive markets underground rather than eliminating them.

Legal and Regulatory Framework

Federal Law: The Farm Bill Foundation

The Agriculture Improvement Act of 2018, codified at 7 U.S.C. § 1639o et seq., provides the federal legal foundation by removing hemp from Schedule I of the Controlled Substances Act. The law defines hemp as cannabis containing no more than 0.3% delta-9 THC on a dry weight basis and explicitly legalizes "all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers" derived from hemp. This language creates the legal basis for hemp-derived delta-8 THC, THCA, and other cannabinoids—they are derivatives of legal hemp, and the statute does not restrict other THC isomers. However, the DEA's position that "synthetically derived" THC remains illegal under 21 U.S.C. § 812 creates ambiguity about chemically converted cannabinoids.

The Controlled Substances Act Tension

The Controlled Substances Act, 21 U.S.C. § 801 et seq., lists "tetrahydrocannabinols" in Schedule I without specifying isomers. The DEA interprets this to include all THC isomers except those specifically exempted. The Farm Bill created an exemption for hemp and its derivatives, but the DEA argues this exemption does not extend to synthetic cannabinoids. Courts have not definitively resolved whether delta-8 THC produced through isomerization of hemp-derived CBD constitutes a "synthetic" cannabinoid or a hemp derivative. The U.S. Court of Appeals for the Ninth Circuit declined to address this question in AK Futures LLC v. Boyd Street Distro, LLC (2022), leaving the legal status uncertain.

Pennsylvania State Law

Pennsylvania has no statute explicitly addressing hemp-derived intoxicating cannabinoids. The Medical Marijuana Act, 35 P.S. § 10231.101 et seq., establishes the medical cannabis program but does not regulate hemp. The Plant Sanitation Act, 3 Pa.C.S. § 101 et seq., authorizes the Department of Agriculture to regulate hemp cultivation but does not address finished products. This statutory silence means hemp THC products are legal by default—not explicitly authorized, but not prohibited. Keefer's bill would fill this gap by creating the first comprehensive state framework.

Federalism and State Authority

States retain authority to regulate hemp more restrictively than federal law, and several have exercised this power to ban intoxicating hemp-derived cannabinoids. The Farm Bill's Section 10114 explicitly preserves state authority, stating that nothing in the law preempts state hemp regulations. Pennsylvania can therefore prohibit, regulate, or ignore hemp THC products as a matter of state policy. The question is not legal authority but political will and policy judgment.

State-by-State Breakdown: How Other States Handle Hemp THC

States have adopted widely divergent approaches to hemp-derived intoxicating cannabinoids, ranging from outright prohibition to comprehensive regulation to continued inaction.

Prohibition States

At least 15 states have banned delta-8 THC and similar hemp-derived intoxicants. Alaska prohibited delta-8 THC through emergency regulations in 2021. Colorado banned delta-8 THC in 2021, with the Department of Public Health and Environment determining it constitutes a synthetic controlled substance. New York prohibited delta-8 THC in 2021 through guidance from the Office of Cannabis Management, later codified in regulations. These bans typically define prohibited substances broadly to include delta-8 THC, delta-10 THC, THC-O, and other isomers, while exempting delta-9 THC in compliant hemp products (below 0.3%).

Regulatory States

Several states have implemented regulatory frameworks that preserve legal access while establishing safety standards. Kentucky enacted KRS 260.850 et seq. in 2023, creating a licensing system for hemp processors and retailers, requiring third-party testing, limiting edibles to 10mg THC per serving, and restricting sales to adults 21 and older. Louisiana established regulations through the Department of Agriculture in 2022, requiring product registration, testing for contaminants, and age verification. Minnesota passed legislation in 2022 limiting edibles to 5mg THC per serving and 50mg per package, with testing and labeling requirements. Virginia implemented regulations in 2023 requiring hemp THC products to be sold only in licensed cannabis dispensaries, effectively limiting availability while maintaining legal status.

Gray Area States

Many states, including Pennsylvania until Keefer's proposal, have taken no definitive action. In these jurisdictions, hemp THC products exist in legal limbo—not explicitly authorized but not prohibited. This category includes Florida, Georgia, Indiana, Missouri, Nebraska, South Carolina, Tennessee, and Texas, among others. Market conditions vary widely in these states depending on local enforcement, retailer caution, and prosecutorial discretion.

Pennsylvania's Position

Pennsylvania currently falls in the gray area category but appears poised to join regulatory states if Keefer's legislation advances. The Commonwealth's approach will influence neighboring states including Ohio, Maryland, West Virginia, and New Jersey, all of which are grappling with similar questions.

Market and Business Implications

Impact on Hemp Businesses

Keefer's regulatory framework would impose new costs on hemp businesses while providing legal certainty and legitimacy that could expand the market long-term. Registration fees, testing costs, and compliance expenses would increase operating costs, particularly for smaller retailers and manufacturers. Third-party testing typically costs $200-500 per batch, depending on the panel of tests required. For manufacturers producing multiple product SKUs, annual testing costs could reach $10,000-50,000. Registration fees would add additional expenses. However, regulation could benefit established businesses by creating barriers to entry for fly-by-night operators and building consumer confidence. A legal, regulated market typically grows larger than an unregulated gray market, as mainstream retailers and risk-averse consumers enter.

Medical Marijuana Industry Competition

Pennsylvania's medical cannabis operators view hemp THC regulation as both threat and opportunity. Strict regulations that increase hemp product costs could reduce price competition with medical cannabis. However, a well-regulated hemp market could still undercut medical prices due to lower tax burdens and fewer licensing restrictions. Some medical operators have launched hemp brands to compete in both markets. Trulieve, which operates medical dispensaries in Pennsylvania, sells hemp-derived products in other states. Curaleaf has similarly diversified. These multi-state operators could leverage existing infrastructure to dominate a regulated Pennsylvania hemp market. Smaller, Pennsylvania-only medical operators lack this flexibility and could face intensified competition.

Retail Landscape Changes

Age restrictions and storage requirements would force many current hemp THC retailers to restructure operations or exit the market. Convenience stores and gas stations that currently display hemp products alongside CBD and kratom would need to implement age verification systems and secure storage. Some retailers may determine that compliance costs exceed profit margins and discontinue hemp THC products. This could consolidate the market into dedicated smoke shops, CBD stores, and potentially medical dispensaries if regulations permit. The legislation could also create opportunities for new retail formats—licensed hemp dispensaries similar to medical cannabis stores but with lower barriers to entry.

Investment and Capital Flows

Regulatory clarity typically attracts institutional capital that avoids legal gray areas. Pennsylvania hemp businesses operating under a clear regulatory framework could access bank loans, credit card processing, and investment capital more readily than in the current uncertain environment. However, federal prohibition of marijuana under the Controlled Substances Act continues to complicate banking and investment, even for hemp businesses. Until Congress passes legislation like the SAFER Banking Act, hemp businesses will face some financial services restrictions regardless of state regulation.

Tax Revenue Potential

Keefer's proposal does not include a specific excise tax on hemp THC products, but future amendments could add tax provisions. Pennsylvania's medical marijuana program does not impose a specific cannabis tax—products are subject only to the state's 6% sales tax. Applying the same treatment to hemp products would generate modest revenue. If Pennsylvania imposed a 10% excise tax on hemp THC products, annual revenue could reach $7-12 million based on current market size estimates. This pales in comparison to adult-use marijuana tax revenue in other states but could fund regulatory oversight.

What Experts and Stakeholders Say

Cannabis policy experts generally support regulatory frameworks over prohibition for hemp-derived intoxicants, citing evidence that bans drive markets underground without eliminating demand. Paul Armentano, deputy director of the National Organization for the Reform of Marijuana Laws, has stated that hemp THC products emerged because of failed marijuana prohibition policies. According to Armentano, the solution is comprehensive cannabis legalization rather than piecemeal hemp regulation, but regulatory frameworks represent a harm-reduction approach preferable to prohibition. Dr. Peter Grinspoon, a physician and cannabis specialist at Massachusetts General Hospital, has emphasized the importance of testing requirements for hemp products. According to Grinspoon, the lack of quality control in unregulated hemp markets poses genuine health risks, particularly from pesticides, heavy metals, and inaccurate potency labeling. Shawn Hauser, a cannabis attorney with Vicente LLP, has advised multiple states on hemp regulation. According to Hauser, successful frameworks balance consumer protection with market access, avoid regulatory capture by existing cannabis industries, and include reasonable compliance timelines for businesses to adapt. The Hemp Industries Association has advocated for federal regulatory clarity rather than a state-by-state patchwork. According to the organization, inconsistent state regulations create compliance challenges for businesses operating across state lines and confuse consumers about product legality. Pennsylvania-specific stakeholders have expressed varied positions. Patrick Nightingale, executive director of the Pittsburgh chapter of NORML, has supported Keefer's regulatory approach as a pragmatic step toward broader cannabis reform. According to Nightingale, hemp THC regulation could serve as a pilot program demonstrating that cannabis products can be sold safely to adults. Meredith Buettner, executive director of the Pennsylvania Cannabis Coalition, has called for integrating hemp THC products into a comprehensive adult-use cannabis framework rather than creating separate regulatory systems. According to Buettner, dual systems create unnecessary complexity and administrative costs.

What's Next: Legislative Path and Timeline

Senator Keefer's Pennsylvania Hemp and Cannabinoid Act faces a multi-stage legislative process that could extend into 2027 before any regulations take effect. The immediate next step involves gathering cosponsors. Keefer circulated her memorandum to all 50 state senators on September 28, 2026, requesting support. Bills with broad bipartisan cosponsorship advance more readily than those with narrow backing. Keefer will likely seek at least 15-20 cosponsors before formal introduction. Following introduction, the bill would be referred to the Senate Agriculture and Rural Affairs Committee, which Keefer chairs. This positioning gives her significant control over the legislation's advancement. The committee would hold public hearings, allowing stakeholders to testify. Expect testimony from hemp businesses, medical cannabis operators, public health officials, law enforcement, and consumer advocates. Committee consideration typically takes 4-8 weeks. The committee could approve the bill as introduced, amend it based on testimony, or table it indefinitely. If approved, the bill would advance to the full Senate for floor debate and vote. Senate passage would send the legislation to the Pennsylvania House of Representatives, where it would undergo a similar committee process in the House Agriculture and Rural Affairs Committee. The House could pass the Senate version unchanged, amend it and return it to the Senate, or reject it. If both chambers pass different versions, a conference committee would reconcile differences. The final compromise would require approval by both chambers before reaching the governor's desk. Governor Josh Shapiro, a Democrat, has not taken a public position on hemp THC regulation but has supported medical marijuana expansion and expressed openness to adult-use cannabis legalization. Shapiro would likely sign a reasonable regulatory framework, particularly one with bipartisan support. The entire legislative process could take 6-12 months under favorable conditions, meaning enactment in mid-2027 at the earliest. Following enactment, the Department of Agriculture would need to develop implementing regulations, a process typically requiring 6-12 additional months. Regulations would undergo public comment periods and review. Businesses would then need compliance timelines to meet new requirements—likely 6-12 months after final regulations take effect. This means full implementation might not occur until 2028.

Potential Obstacles and Opposition

Several factors could derail or significantly delay the legislation. Opposition from medical cannabis operators could intensify if they perceive the regulatory framework as too permissive. These businesses have significant lobbying resources and political influence. Prohibition advocates, including some law enforcement groups and social conservatives, may oppose any framework that preserves legal access to intoxicating products. They could push for amendments that effectively ban products through unworkable requirements. Federal regulatory changes could alter the landscape. If the DEA or FDA takes aggressive enforcement action against hemp THC products nationally, Pennsylvania might pause its regulatory efforts. Conversely, if Congress passes legislation explicitly legalizing and regulating hemp-derived intoxicants, state action could become moot. Budget constraints could pose challenges. Implementing a new regulatory program requires funding for staff, laboratory oversight, and enforcement. If the legislation does not include adequate funding mechanisms, the Department of Agriculture might lack resources for effective implementation.

Alternative Scenarios

If Keefer's bill fails, several alternative paths exist. The Department of Agriculture or Department of Health could attempt regulatory action through existing statutory authority, though legal challenges would likely follow. Emergency regulations could be issued if officials determine hemp THC products pose imminent public health risks. The legislature could pursue prohibition instead of regulation, particularly if high-profile adverse events occur. A ban would be simpler to implement than a regulatory framework but would drive the market underground. Pennsylvania could also maintain the status quo indefinitely, leaving hemp THC products in legal limbo. This outcome becomes less likely as more states take definitive action and pressure builds for clarity. Adult-use cannabis legalization could subsume the hemp THC question. If Pennsylvania legalizes recreational marijuana, hemp-derived products could be integrated into that framework. However, adult-use legalization faces steeper political obstacles than hemp regulation.

Further Reading and Primary Sources

• Agriculture Improvement Act of 2018 (Farm Bill), Public Law 115-334, full text at https://www.congress.gov/bill/115th-congress/house-bill/2
• Pennsylvania Medical Marijuana Act, 35 P.S. § 10231.101 et seq., full text at https://www.legis.state.pa.us/cfdocs/legis/li/uconsCheck.cfm?yr=2016&sessInd=0&act=16
• Pennsylvania Department of Agriculture Hemp Program, information and regulations at https://www.agriculture.pa.gov/Plants_Land_Water/industrial_hemp/Pages/default.aspx
• Drug Enforcement Administration Interim Final Rule on Hemp, 85 Fed. Reg. 51639 (August 21, 2020), available at https://www.federalregister.gov/documents/2020/08/21/2020-18085/implementation-of-the-agriculture-improvement-act-of-2018
• U.S. Department of Agriculture Hemp Production Program, 7 CFR Part 990, information at https://www.ams.usda.gov/rules-regulations/hemp
• Pennsylvania Department of Health Medical Marijuana Program data and reports at https://www.health.pa.gov/topics/programs/Medical%20Marijuana/Pages/Medical%20Marijuana.aspx
• National Conference of State Legislatures state hemp and CBD laws database at https://www.ncsl.org/health/state-medical-cannabis-laws
• Senator Dawn Keefer official website and press releases at https://www.senatorwkeefer.com/
• Pennsylvania General Assembly bill tracking and full text at https://www.legis.state.pa.us/
• Marijuana Moment coverage of Pennsylvania hemp policy at https://www.marijuanamoment.net/